{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:52:29Z","timestamp":1783493549702,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:00:00Z","timestamp":1625961600000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special","doi-asserted-by":"publisher","award":["2018\u20131-2061"],"award-info":[{"award-number":["2018\u20131-2061"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7191002"],"award-info":[{"award-number":["7191002"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600213"],"award-info":[{"award-number":["81600213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970292"],"award-info":[{"award-number":["81970292"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["DFL20180601"],"award-info":[{"award-number":["DFL20180601"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["ZYLX201710"],"award-info":[{"award-number":["ZYLX201710"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["ZYLX201710"],"award-info":[{"award-number":["ZYLX201710"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z181100001718060"],"award-info":[{"award-number":["Z181100001718060"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["PZ2019005"],"award-info":[{"award-number":["PZ2019005"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ahj.2020.06.005","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T19:59:37Z","timestamp":1592683177000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction"],"prefix":"10.1016","volume":"227","author":[{"given":"Yan","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoping","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.06.005_bb0005","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2459\/JCM.0000000000000533","volume":"18","author":"De Luca","year":"2017","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.ahj.2020.06.005_bb0010","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0015","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2018.12.023","article-title":"Post-procedural bivalirudin infusion at full or low regimen in patients with acute coronary syndrome","volume":"73","author":"Gargiulo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.06.005_bb0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.06.005_bb0030","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0035","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/eurheartj\/ehx799","article-title":"Periprocedural myocardial infarction and injury in elective coronary stenting","volume":"39","author":"Zeitouni","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.06.005_bb0040","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jcin.2015.02.030","volume":"8","author":"Franchi","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.06.005_bb0045","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH Study","volume":"67","author":"Rollini","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0055","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1055\/s-0038-1657768","article-title":"Pharmacodynamic Effects of a 6-hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study)","volume":"118","author":"Sumaya","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2020.06.005_bb0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.06.005_bb0065","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Meharn","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.06.005_bb0070","doi-asserted-by":"crossref","unstructured":"GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82, doi:https:\/\/doi.org\/10.1056\/NEJM199309023291001.","DOI":"10.1056\/NEJM199309023291001"},{"key":"10.1016\/j.ahj.2020.06.005_bb0075","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention","volume":"355","author":"Montalescot","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.06.005_bb0085","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.06.005_bb0090","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0095","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0100","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.06.005_bb0105","article-title":"Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post-hoc analysis of the randomized INNOVATION trial","volume":"98","author":"Song","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ahj.2020.06.005_bb0110","first-page":"766","article-title":"2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction","volume":"47","author":"Chinese Society of Cardiology of Chinese Medical Association","year":"2019","journal-title":"Zhonghua xin xue guan bing za zhi"},{"key":"10.1016\/j.ahj.2020.06.005_bb0115","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcin.2009.11.012","article-title":"Enoxaparin in primary and facilitated percutaneous coronary intervention: a formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)","volume":"3","author":"Montalescot","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.06.005_bb0125","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/01.CIR.0000087601.45803.86","article-title":"Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial","volume":"108","author":"Tcheng","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.06.005_bb0130","first-page":"659","article-title":"Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials","volume":"6","author":"Ducrocq","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.ahj.2020.06.005_bb0135","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.amjcard.2014.07.061","article-title":"Postprocedural anticoagulation for specific therapeutic indications after revascularization for ST-segment elevation myocardial infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial)","volume":"114","author":"Madhavan","year":"2014","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2020.06.005_bb0140","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/2047487318763823","article-title":"Safety of early discharge after primary angioplasty in low-risk patients with ST-segment elevation myocardial infarction: A meta-analysis of randomised controlled trials","volume":"25","author":"Gong","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"22","key":"10.1016\/j.ahj.2020.06.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012054","article-title":"Comparison of in-hospital mortality and length of stay in acute ST-segment-elevation myocardial infarction among urban teaching hospitals in China and the United States","volume":"8","author":"Han","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.ahj.2020.06.005_bb0150","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jacc.2015.01.028","article-title":"Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the national cardiovascular data registry","volume":"65","author":"Swaminathan","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijcard.2016.11.276","article-title":"Mar\u00eda Jes\u00fas Valero-Masa, Jes\u00fas Vel\u00e1squez-Rodr\u00edguez, et al. Very low risk ST-segment elevation myocardial infarction? It exists and may be easily identified","volume":"228","author":"D\u00edez-Delhoyo","year":"2017","journal-title":"Int J Cardiol"},{"issue":"15","key":"10.1016\/j.ahj.2020.06.005_bb0160","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJMoa1907775","article-title":"Complete revascularization with multivessel PCI for myocardial infarction","volume":"381","author":"Mehta","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0165","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jacc.2018.12.022","article-title":"Anticoagulation, the unknown of the antithrombotic equation after stenting of an acute coronary syndrome","volume":"73","author":"Montalescot","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1026543107533","article-title":"The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design","volume":"10","author":"Cohen","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2020.06.005_bb0175","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0735-1097(03)01040-4","article-title":"The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial","volume":"42","author":"Cohen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0185","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacc.2013.03.041","article-title":"Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51","volume":"62","author":"Gibson","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0190","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4244\/EIJV12I9A186","article-title":"Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb\/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial","volume":"12","author":"Schoos","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2020.06.005_bb0195","first-page":"650","article-title":"Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial","volume":"6","author":"Madhavan","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.ahj.2020.06.005_bb0200","doi-asserted-by":"crossref","first-page":"20140470","DOI":"10.1259\/bjr.20140470","article-title":"Cardiac MR assessment of microvascular obstruction","volume":"88","author":"Abbas","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(11)61335-4","article-title":"Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial","volume":"379","author":"Greenwood","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.06.005_bb0210","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/heartjnl-2013-304717","article-title":"Key recommendations and evidence from the NICE guideline for the acute management of ST-segment-elevation myocardial infarction","volume":"100","author":"Harker","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2020.06.005_bb0215","first-page":"214","article-title":"2018 Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1253\/circj.CJ-66-0053","article-title":"Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011)","volume":"77","author":"JCS Joint Working Group","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2020.06.005_bb0225","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.06.005_bb0230","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.06.005_bb0235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijcard.2016.01.206","article-title":"Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials","volume":"209","author":"Zhang","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0240","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00392-018-1251-1","article-title":"Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials","volume":"107","author":"Nuhrenberg","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0245","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.06.005_bb0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcin.2014.07.018","article-title":"Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction","volume":"8","author":"Le May","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.06.005_bb0255","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006054","article-title":"Outcomes and prognostic impact of prophylactic oral anticoagulation in anterior ST-segment elevation myocardial infarction patients with left ventricular dysfunction","volume":"6","author":"Shavadia","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2020.06.005_bb0260","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2020.06.005_bb0265","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2020.06.005_bb0270","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.06.005_bb0275","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0280","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0285","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction","volume":"358","author":"Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.06.005_bb0290","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/CIRCINTERVENTIONS.108.847582.108.847582","volume":"2","author":"Le May","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.06.005_bb0295","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","article-title":"Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction","volume":"35","author":"Schulz","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.06.005_bb0300","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0305","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.293.4.427","article-title":"Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation","volume":"293","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.06.005_bb0310","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0315","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMoa0706816","article-title":"Facilitated PCI in patients with ST-elevation myocardial infarction","volume":"358","author":"Ellis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.06.005_bb0320","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.06.005_bb0325","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","article-title":"Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial","volume":"372","author":"Van't Hof","year":"2008","journal-title":"Lancet"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032030185X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032030185X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:23Z","timestamp":1762077443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287032030185X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":65,"alternative-id":["S000287032030185X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.06.005","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}